Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Castle Biosciences Signs Collaboration And License Agreement With SciBase To Develop Atopic Dermatitis Flare Prediction Test Using Electrical Impedance Spectroscopy Technology

Author: Benzinga Newsdesk | June 16, 2025 04:32pm

Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced that it has entered into a collaboration and license agreement with SciBase Holding AB ("SciBase") utilizing SciBase's Electrical Impedance Spectroscopy technology which includes both desktop and point-of-care instruments. The initial goal of the collaboration is to advance the development of a diagnostic test that predicts flares in patients diagnosed with atopic dermatitis (AD).

Posted In: CSTL


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist